CPA
GBIO

Capital Performance Advisors’s Generation Bio GBIO Stock Holding History

Capital Performance Advisors’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$111 – 1112
2024
Q3 		$111 Buy
+5
New +$132 ﹤0.01% 2678

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Performance Advisors's GBIO Position: Q4 2024 in Review

Capital Performance Advisors sold out of Generation Bio (GBIO) in Q4 2024, closing a stake of 5 shares — an estimated $111 sold.

Capital Performance Advisors first reported a position in GBIO in Q3 2024 and held it in 1 quarter. The position peaked at $111 in Q3 2024. 78 funds tracked by Wall St. Rank hold GBIO as of Q4 2024.

  • Capital Performance Advisors reported no remaining Generation Bio position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 5 Generation Bio shares in Q4 2024, an estimated $111.
  • Capital Performance Advisors first reported a position in Generation Bio in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Generation Bio position peaked at $111 in Q3 2024.
  • 78 funds tracked by Wall St. Rank held Generation Bio as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.